Saturday, October 18, 2014 2:48:12 AM
Teva and Intellipharmaceutics are incorporating technology to curb abuse and prevent overdoses.
October 9, 2014
Click For barrons.com Link
Maxim Group
Teva Pharmaceutical Industries announced they have initiated a rolling New Drug Application submission for CEP-33237 (hydrocodone bitartrate), which is expected to be completed by year-end 2014.
Teva’s (ticker: TEVA ) (rated at Buy) CEP-33237, an investigational, 12-hour, acetaminophen-free, extended release hydrocodone will be the first approved pain killer with advanced abuse deterrent technology (ADT). The drug can be taken twice daily, and in previously reported intranasal (snorting) and oral (crushing) HAL (Human Abuse Liability) studies, showed significantly lower abuse potential in recreational users.
However, the abuse potential for taking the whole pill was the same as placebo. This suggests CEP-33237 can prevent hard-core abusers who need to snort, crush and inject to get high but does not preclude the development of addiction by recreational or nonabusive users (patients with chronic pain). However, CEP-33237 is a step in the right direction.
The competition appeared to have moved past Intellipharmaceutics International ( IPCI ) late this summer, and we downgraded the company to Hold (combined with lower-than-expected sales of generic Focalin XR). However, our meeting with management and a description of their first of its kind Paradoxical OverDose Resistance Activating System (PODRAS) technology to prevent overdose, drove us to re-evaluate the company’s ability to compete in the ADT space. This combined with changes in key management, including replacing the chief financial officer, prompted us to change our rating back to Buy.
What is PODRAS? While management did not disclose the details of exactly how it works, the basic concept is that it prevents a potential overdose. PODRAS, as presented to us, causes the patient to have the analgesic effect of only one pill even if they abuse the drug by taking a lot of pills at once. For, example, Intellipharmaceutics’ Rexista uses a similar ADT IntelliMatrix to CEP-33237, but both drugs only prevent manipulating the pill to snort, inject and/or crush to get high. Neither ADT alone can prevent overdose or development of abuse when taken whole. Rexista incorporates the PODRAS technology which is what differentiates it from CEP-33237. Drug users can take all they like but can’t get high or overdose.
Why does PODRAS matter? Intellipharmaceutics discussed with us at great length the potential of the PODRAS platform and the implications to everything from Tylenol (what if you could prevent accidental overdose and eliminate liver toxicity?) to the regulatory concerns about multiple dosing of narcotics like Oxycodone. The data we discussed were impressive, and we see PODRAS potentially changing how drugs are manufactured.
TRUTH
I've never claimed to have all the answers but feel i'm beginning to corner the market in questions worthy of solutions.
Recent TTNP News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:33:11 PM
- Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria • GlobeNewswire Inc. • 01/25/2024 09:29:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:59:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 10:13:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:30:20 PM
- Titan Pharmaceuticals Announces Reverse Stock Split and Ratio • GlobeNewswire Inc. • 12/28/2023 09:15:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2023 09:47:46 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/17/2023 09:03:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 09:05:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:33:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:31:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:29:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:25:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:23:37 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 10/24/2023 09:26:34 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/23/2023 07:07:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:08:35 PM
- Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors • GlobeNewswire Inc. • 10/16/2023 08:37:23 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 10/04/2023 09:30:18 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 09/19/2023 08:41:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 08:45:22 PM
- Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock • GlobeNewswire Inc. • 09/18/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 09:30:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2023 08:28:25 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM